دورية أكاديمية
أعرض في EDS

Potentially inappropriate prescribing for adults living with diabetes mellitus: a scoping review.

التفاصيل البيبلوغرافية
العنوان: Potentially inappropriate prescribing for adults living with diabetes mellitus: a scoping review.
المؤلفون: Ayalew MB; Pharmacy, School of Rural Medicine, University of New England, Armidale, NSW 2351, Australia.; Department of Clinical Pharmacy, School of Pharmacy, University of Gondar, Gondar, Ethiopia., Spark MJ; Pharmacy, School of Rural Medicine, University of New England, Armidale, NSW 2351, Australia., Quirk F; School of Rural Medicine, University of New England, Armidale, NSW 2351, Australia., Dieberg G; Biomedical Science, School of Science and Technology, University of New England, Armidale, NSW 2351, Australia. gdieberg@une.edu.au.
المصدر: International journal of clinical pharmacy [Int J Clin Pharm] 2022 Aug; Vol. 44 (4), pp. 860-872. Date of Electronic Publication: 2022 Jul 01.
نوع المنشور: Journal Article; Review; Systematic Review
اللغة: English
بيانات الدورية: Publisher: Springer Country of Publication: Netherlands NLM ID: 101554912 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2210-7711 (Electronic) NLM ISO Abbreviation: Int J Clin Pharm Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Dordrecht : Springer
مواضيع طبية MeSH: Diabetes Mellitus*/drug therapy , Diabetes Mellitus*/epidemiology , Inappropriate Prescribing*/prevention & control, Adult ; Databases, Factual ; Drug Interactions ; Humans ; Polypharmacy ; Potentially Inappropriate Medication List
مستخلص: Background: People living with diabetes often experience multiple morbidity and polypharmacy, increasing their risk of potentially inappropriate prescribing. Inappropriate prescribing is associated with poorer health outcomes.
Aim: The aim of this scoping review was to explore and map studies conducted on potentially inappropriate prescribing among adults living with diabetes and to identify gaps regarding identification and assessment of potentially inappropriate prescribing in this group.
Method: Studies that reported any type of potentially inappropriate prescribing were included. Studies conducted on people aged < 18 years or with a diagnosis of gestational diabetes or prediabetes were excluded. No restrictions to language, study design, publication status, geographic area, or clinical setting were applied in selecting the studies. Articles were systematically searched from 11 databases.
Results: Of the 190 included studies, the majority (63.7%) were conducted in high-income countries. None of the studies used an explicit tool specifically designed to identify potentially inappropriate prescribing among people with diabetes. The most frequently studied potentially inappropriate prescribing in high-income countries was contraindication while in low- and middle-income countries prescribing omission was the most common. Software and websites were mostly used for identifying drug-drug interactions. The specific events and conditions that were considered as inappropriate were inconsistent across studies.
Conclusion: Contraindications, prescribing omissions and dosing problems were the most commonly studied types of potentially inappropriate prescribing. Prescribers should carefully consider the individual prescribing recommendations of medications. Future studies focusing on the development of explicit tools to identify potentially inappropriate prescribing for adults living with diabetes are needed.
(© 2022. The Author(s).)
References: Taylor LK, Kawasumi Y, Bartlett G, et al. Inappropriate prescribing practices: the challenge and opportunity for patient safety. Healthc Q (Toronto Ont). 2005;8:81–5. (PMID: 10.12927/hcq..17669)
Formiga F, Vidal X, Agusti A, et al. Inappropriate prescribing in elderly people with diabetes admitted to hospital. Diabet Med. 2016;33:655–62. (PMID: 10.1111/dme.12894)
Aronson JK. Medication errors: what they are, how they happen, and how to avoid them? QJM. 2009;102:513–21. (PMID: 10.1093/qjmed/hcp052)
O’Connor MN, Gallagher P, O’Mahony D. Inappropriate prescribing: criteria, detection and prevention. Drugs Aging. 2012;29:437–52. (PMID: 10.2165/11632610-000000000-00000)
Cahir C, Bennett K, Teljeur C, et al. Potentially inappropriate prescribing and adverse health outcomes in community dwelling older patients. Br J Clin Pharmacol. 2014;77:201–10. (PMID: 10.1111/bcp.12161)
Hedna K, Hakkarainen KM, Gyllensten H, et al. Potentially inappropriate prescribing and adverse drug reactions in the elderly: A population-based study. Eur J Clin Pharmacol. 2015;71:1525–33. (PMID: 10.1007/s00228-015-1950-8)
Bradley MC, Fahey T, Cahir C, et al. Potentially inappropriate prescribing and cost outcomes for older people: A cross-sectional study using the Northern Ireland Enhanced Prescribing Database. Eur J Clin Pharmacol. 2012;68:1425–33. (PMID: 10.1007/s00228-012-1249-y)
Barnett K, Mercer SW, Norbury M, et al. Epidemiology of multimorbidity and implications for health care, research, and medical education: A cross-sectional study. The Lancet. 2012;380:37–43. (PMID: 10.1016/S0140-6736(12)60240-2)
Guthrie B, Makubate B, Hernandez-Santiago V, et al. The rising tide of polypharmacy and drug-drug interactions: Population database analysis 1995–2010. BMC Med. 2015;13:74. (PMID: 10.1186/s12916-015-0322-7)
Martirosyan L, Braspenning J, Denig P, et al. Prescribing quality indicators of type 2 diabetes mellitus ambulatory care. Qual Saf Health Care. 2008;17:318–23. (PMID: 10.1136/qshc.2007.024224)
International Diabetes Federation. IDF Diabetes Atlas, 9th edn. 2019 February 12/2020. https://www.diabetesatlas.org . Accessed 18.06.2021.
Bommer C, Sagalova V, Heesemann E, et al. Global economic burden of diabetes in adults: projections from 2015 to 2030. Diabetes Care. 2018;41:963–70. (PMID: 10.2337/dc17-1962)
Cho NH, Shaw JE, Karuranga S, et al. IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract. 2018;138:271–81. (PMID: 10.1016/j.diabres.2018.02.023)
Ayele Y, Melaku K, Dechasa M, et al. Assessment of drug related problems among type 2 diabetes mellitus patients with hypertension in Hiwot Fana Specialized University Hospital, Harar, Eastern Ethiopia. BMC Res Notes. 2018;11:728. (PMID: 10.1186/s13104-018-3838-z)
Huri HZ, Ling LC. Drug-related problems in type 2 diabetes mellitus patients with dyslipidemia. BMC Public Health. 2013;13:1192. DOI: https://doi.org/10.1186/1471-2458-13-1192 . (PMID: 10.1186/1471-2458-13-1192)
Zaman Huri H, Fun Wee H. Drug related problems in type 2 diabetes patients with hypertension: a cross-sectional retrospective study. BMC Endocr Disord. 2013;13:2. DOI: https://doi.org/10.1186/1472-6823-13-2 . (PMID: 10.1186/1472-6823-13-2)
Inamdar S, Kulkarni R. Drug related problems in elderly patients with type 2 diabetes mellitus. J Diabetol. 2016;7:1–12.
Ananchaisarp T, Duangkamsee N, Burapakiat B, et al. Prevalence of under-prescription in elderly type 2 diabetic patients in the primary care unit of a university hospital. J Health Sci Med Res. 2018;36:259–67. (PMID: 10.31584/jhsmr.2018.36.4.22)
Peters, Michah DJ, Godfrey C, et al. Chapter 11: Scoping Reviews. In: Aromataris E, Munn Z, editors. Joanna Briggs Institute Reviewer’s Manual. 2017. https://reviewersmanual.joannabriggs.org/ . Accessed 17.02.2019.
Ayalew MB, Dieberg G, Quirk F, et al. Potentially inappropriate prescribing for adults with diabetes mellitus: a scoping review protocol. JBI Evid Synthesis. 2020;18:1557–65. (PMID: 10.11124/JBISRIR-D-19-00136)
Serajuddin U, Hamadeh N. New World Bank country classifications by income level: 2020–2021. July 2020. https://blogs.worldbank.org/opendata/new-world-bank-country-classifications-income-level-2020-2021 . Accessed 05.08.2021.
American Diabetes Association. Standards of medical care in diabetes—2019. Diabetes Care. 2019;42:1–193. (PMID: 10.2337/dc19-Sint01)
International Diabetes Federation. Recommendations for managing type 2 diabetes in primary care. 2017. http://www.idf.org/managing-type2-diabetes . Accessed 12.09.2019.
Mori AL, Carvalho RC, Aguiar PM, et al. Potentially inappropriate prescribing and associated factors in elderly patients at hospital discharge in Brazil: A cross-sectional study. Int J Clin Pharm. 2017;39:386–93. (PMID: 10.1007/s11096-017-0433-7)
Kara O, Arik G, Kizilarslanoglu MC, et al. Potentially inappropriate prescribing according to the STOPP/START criteria for older adults. Aging Clin Exp Res. 2016;28:761–8. (PMID: 10.1007/s40520-015-0475-4)
Blundell DB. Medication review according to STOPP-START criteria in older patients from the dose administration aids service of a community pharmacy. Farmaceuticos Comunitarios. 2015;7:31–6.
Marroquín EC, Iglesia NM, Cobos LP. Adequacy of medication in patients 65 years or older in teaching health centers in Cáceres, Spain. Rev Esp Salud Publica. 2012;86:419–34.
Karandikar Y, Chaudhari S, Dalal N, et al. Inappropriate prescribing in the elderly: A comparison of two validated screening tools. J Clin Gerontol Geriatr. 2013;4:109–14. (PMID: 10.1016/j.jcgg.2013.04.004)
Liu C-L, Peng L-N, Chen Y-T, et al. Potentially inappropriate prescribing (IP) for elderly medical inpatients in Taiwan: A hospital-based study. Arch Gerontol Geriatr. 2012;55:148–51. (PMID: 10.1016/j.archger.2011.07.001)
Kovačević SV, Simišić M, Rudinski SS, et al. Potentially inappropriate prescribing in older primary care patients. PLoS ONE. 2014;9:e95536. DOI: https://doi.org/10.1371/journal.pone.0095536 . (PMID: 10.1371/journal.pone.0095536)
Frankenthal D, Lerman Y, Lerman Y. The impact of hospitalization on potentially inappropriate prescribing in an acute medical geriatric division. Int J Clin Pharm. 2015;37:60–7. (PMID: 10.1007/s11096-014-0040-9)
López NP, Villán YFV, Menéndez MIG, et al. Potentially inappropriate prescribing in patients over 65 years-old in a primary care health centre. Aten Primaria. 2014;46:290–7.
Luz AC, de Oliveira MG, Noblat L. Prescribing omissions among elderly Brazilian patients at their hospital admission and discharge: Cross-sectional study. Int J Clin Pharm. 2018;40:1596–600. (PMID: 10.1007/s11096-018-0726-5)
Siripala U, Premadasa S, Samaranayake N, et al. Usefulness of STOPP/START criteria to assess appropriateness of medicines prescribed to older adults in a resource-limited setting. Int J Clin Pharm. 2019;41:525–30. (PMID: 10.1007/s11096-019-00786-7)
Roumie CL, Hung AM, Greevy RA, et al. Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: A cohort study. Ann Intern Med. 2012;157:601–10. (PMID: 10.7326/0003-4819-157-9-201211060-00003)
Fick D, Semla T, Beizer J, et al. American Geriatrics Society 2015 updated Beers criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2015;63:2227–46. (PMID: 10.1111/jgs.13702)
Al Khaja KA, Isa HA, Veeramuthu S, et al. Potentially inappropriate prescribing in older adults with hypertension or diabetes mellitus and hypertension in a primary care setting in Bahrain. Med Princ Pract. 2018;27. DOI: https://doi.org/10.1159/000488055 .
Terán-Álvarez L, González-García M, Rivero-Pérez A, et al. Potentially inappropriate prescription according to the “STOP” criteria in heavily polymedicated elderly patients. Semergen. 2016;42:2–10. (PMID: 10.1016/j.semerg.2014.10.018)
Herman H, San IP, Ningsih R, et al. Inappropriate use of the drug to elderly patients with type-II diabetes mellitus in Makassar, Indonesia. Der Pharmacia Lettre. 2016;8:154–8.
Caughey G, Barratt J, Shakib S, et al. Medication use and potentially high risk prescribing in older patients hospitalized for diabetes: A missed opportunity to improve care. Diabet Med. 2017;34:432–9. (PMID: 10.1111/dme.13148)
Caughey GE, Roughead EE, Vitry AI, et al. Comorbidity in the elderly with diabetes: identification of areas of potential treatment conflicts. Diabetes Res Clin Pract. 2010;87:385–93. (PMID: 10.1016/j.diabres.2009.10.019)
Erah PO, Eroje HI. Prescribing of antidiabetic medicines to older diabetes type 2 patients in Lagos, Nigeria. Nig Q J Hosp Med. 2013;23:12–6.
Aqqad SMA, Chen LL, Shafie AA, et al. The use of potentially inappropriate medications and changes in quality of life among older nursing home residents. Clin Interv Aging 2014;9. DOI: https://doi.org/10.2147/CIA.S52356 .
Mudaliar S, Chang AR, Henry RR. Thiazolidinediones, peripheral edema, and type 2 diabetes: incidence, pathophysiology, and clinical implications. Endocr Pract. 2003;9:406–16. (PMID: 10.4158/EP.9.5.406)
Zanchi A, Lehmann R, Philippe J. Antidiabetic drugs and kidney disease: Recommendations of the Swiss Society for Endocrinology and Diabetology. Swiss Med Wkly. 2012;142. DOI: https://doi.org/10.4414/smw.2012.13629 .
Food and Drug Administration. FDA drug safety communication: FDA revises warnings regarding use of the diabetes medicine metformin in certain patients with reduced kidney function. 2016. https://www.fda.gov/media/96771/download . Accessed 18.08.2021.
Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm–2018 executive summary. Endocr Pract. 2018;24:91–121. (PMID: 10.4158/CS-2017-0153)
National Institute for Health and Care Excellence. Type 2 diabetes in adults: management. NICE guideline 2015. https://www.nice.org.uk/guidance/ng28 . Accessed 12.12.2019.
The Royal Australian College of General Practitioners. General practice management of type 2 diabetes: 2016–18. RACGP: East Melbourne, Vic; 2016.
Huang DL, Abrass IB, Young BA. Medication safety and chronic kidney disease in older adults prescribed metformin: a cross-sectional analysis. BMC Nephrol. 2014;15:86. DOI: https://doi.org/10.1186/1471-2369-15-86 . (PMID: 10.1186/1471-2369-15-86)
PLamine F, Lalubin F, Pitteloud N, et al. Chronic kidney disease in type 2 diabetic patients followed-up by primary care physicians in Switzerland: Prevalence and prescription of antidiabetic drugs. Swiss Med Wkly. 2016;146:w14282. DOI: https://doi.org/10.4414/smw.2016.14282 . (PMID: 10.4414/smw.2016.14282)
Ruiz-Tamayo I, Franch-Nadal J, Mata-Cases M, et al. Noninsulin antidiabetic drugs for patients with type 2 diabetes mellitus: Are we respecting their contraindications? J Diabetes Res. 2016;7502489. DOI: https://doi.org/10.1155/2016/7502489 .
Taner N, Çattık BN, Berk B. A contraindication to metformin therapy: Renal impairment-Adherence to prescribing guidelines at a hospital in Turkey. Acta Pharm Sci. 2018;56:63–70.
Hackethal V. Beta-blockers in type 2 Diabetes: Time to Reconsider? 2018. https://www.endocrinologynetwork.com/cardiovascular-health/beta-blockers-type-2-diabetes-time-reconsider . Accessed 06.10.2019.
Thomopoulos C, Parati G, Zanchetti A. Effects of blood-pressure-lowering treatment on outcome incidence in hypertension: Should blood pressure management differ in hypertensive patients with and without diabetes mellitus? Overview and meta-analyses of randomized trials. J Hypertens. 2017;35:922–44. (PMID: 10.1097/HJH.0000000000001276)
Vaccaro O, Boemi M, Cavalot F, et al. The clinical reality of guidelines for primary prevention of cardiovascular disease in type 2 diabetes in Italy. Atherosclerosis. 2008;198:396–402. (PMID: 10.1016/j.atherosclerosis.2007.10.026)
LaMarr B, Valdez C, Driscoll K, et al. Influence of pharmacist intervention on prescribing of angiotensin-converting-enzyme inhibitors, angiotensin II-receptor blockers, and aspirin for diabetic patients. Am J Health Syst Pharm. 2010;67:290–4. (PMID: 10.2146/ajhp090009)
Yeste-Gomez I, Duran-Garcia ME, Muino-Miguez A, et al. Potentially inappropriate prescriptions in the ambulatory treatment of elderly patients. Rev Calid Asist. 2014;29:22–8.
Thomas MC, Weekes AJ, Broadley OJ, et al. The burden of chronic kidney disease in Australian patients with type 2 diabetes (the NEFRON study). Med J Aust. 2006;185:140–4. (PMID: 10.5694/j.1326-5377.2006.tb00499.x)
Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics-2013 update: A report from the American Heart Association. Circulation. 2013;127:e6–245.
Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670–81. (PMID: 10.1016/S0140-6736(10)61350-5)
Kearney PM, Blackwell L, Collins R, et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: A meta-analysis. Lancet. 2008;371:117–25. (PMID: 10.1016/S0140-6736(08)60104-X)
Galvan-Banqueri M, Gonzalez-Mendez AI, Alfaro-Lara ER, et al. Evaluation of the appropriateness of pharmacotherapy in patients with high comorbidity. Aten Primaria. 2013;45:235–43.
Fu AZ, Zhang Q, Davies MJ, et al. Underutilization of statins in patients with type 2 diabetes in US clinical practice: A retrospective cohort study. Curr Med Res Opin. 2011;27:1035–40. (PMID: 10.1185/03007995.2011.567257)
Elnaem M, Nik Mohamed M, Huri H, et al. Patterns of statin therapy prescribing among hospitalized patients with type 2 diabetes mellitus in two Malaysian tertiary hospitals. Trop J Pharm Res. 2017;16:3005–11.
Simons LA, Chung E. Are high coronary risk patients missing out on lipid lowering drugs in Australia? Med J Aust. 2014;201:213–6. (PMID: 10.5694/mja14.00249)
Yimama M, Jarso H, Desse. TA Determinants of drug-related problems among ambulatory type 2 diabetes patients with hypertension comorbidity in South West Ethiopia: A prospective cross sectional study. BMC Res Notes. 2018;11:679. DOI: https://doi.org/10.1186/s13104-018-3785-8 . (PMID: 10.1186/s13104-018-3785-8)
Doellner JF, Dettloff RW, DeVuyst-Miller S, et al. Prescriber acceptance rate of pharmacists’ recommendations. J Am Pharm Assoc. 2017;57:197–202. (PMID: 10.1016/j.japh.2017.03.002)
Salgueiro E, Elizarde BC, Elola AI, et al. The most common STOPP/START criteria in Spain. A review of the literature. Rev Esp Geriatr Gerontol. 2018;53:274–8. (PMID: 10.1016/j.regg.2018.03.001)
Elnaem MH, Mohamed MHN, Huri HZ, et al. Effectiveness and prescription pattern of lipid-lowering therapy and its associated factors among patients with type 2 diabetes mellitus in Malaysian primary care settings. Ther Clin Risk Manag. 2019;15. DOI: https://doi.org/10.2147/TCRM.S182716 .
Anderson SL, Marrs JC, Chachas CR, et al. Evaluation of a pharmacist-led intervention to improve statin use in persons with diabetes. J Manag Care Spec Pharm. 2020;26:910–7.
Elnaem MH, Mohamed MHN, Huri HZ. Pharmacist-led academic detailing improves statin therapy prescribing for Malaysian patients with type 2 diabetes: Quasi-experimental design. PLoS ONE. 2019;14:e0220458. DOI: https://doi.org/10.1371/journal.pone.0220458 . (PMID: 10.1371/journal.pone.0220458)
Kochetkov AI, De VA, Voevodina NY, et al. The application of the STOPP/START criteria in the elderly patients with type 2 diabetes mellitus and essential hypertension at the endocrinology department of a multidisciplinary hospital. Arterial Hypertens. 2019;25:214–24.
Mwita JC, Godman B, Esterhuizen TM. Statin prescription among patients with type 2 diabetes in Botswana: Findings and implications. BMC Endocr Disord. 2020;20:1–9. (PMID: 10.1186/s12902-020-0516-7)
Harder S, Saal K, Blauth E, et al. Appropriateness and surveillance of medication in a cohort of diabetic patients on polypharmacy. Int J Clin Pharmacol Ther. 2009;47:104–10. (PMID: 10.5414/CPP47104)
Bulatova NR, Al Motassem FY, AbuRuz SM. Antiplatelet therapy for primary and secondary prevention in Jordanian patients with diabetes mellitus. Thromb Res. 2007;121:43–50. (PMID: 10.1016/j.thromres.2007.03.006)
Woodward A, Bayley D, Overend L, et al. Antiplatelet drug use in a diabetic clinic. QJM. 2007;100:547–50. (PMID: 10.1093/qjmed/hcm058)
Pasina L, Novella A, Elli C, et al. Inappropriate use of antiplatelet agents for primary prevention in nursing homes: An Italian multicenter observational study. Geriatr Gerontol Int. 2020;20:828–32. (PMID: 10.1111/ggi.13984)
Haggerty SA, Cerulli J, Zeolla MM, et al. Community pharmacy target intervention program to improve aspirin use in persons with diabetes. J Am Pharm Assoc. 2005;45:17–22. (PMID: 10.1331/1544345052843020)
van Roozendaal BW, Krass I. Development of an evidence-based checklist for the detection of drug related problems in type 2 diabetes. Pharm World Sci. 2009;31:580–95. (PMID: 10.1007/s11096-009-9312-1)
Leitão CB, Krahe AL, Nabinger GB, et al. Aspirin therapy is still underutilized among patients with type 2 diabetes. Arq Bras Endocrinol Metabol. 2006;50:1014–9. (PMID: 10.1590/S0004-27302006000600006)
Faragon JJ, Waite NM, Hobson EH, et al. Improving aspirin prophylaxis in a primary care diabetic population. Pharmacotherapy. 2003;23:73–9. (PMID: 10.1592/phco.23.1.73.31923)
Klinke JA, Johnson JA, Guirguis LM, et al. Underuse of aspirin in type 2 diabetes mellitus: Prevalence and correlates of therapy in rural Canada. Clin Ther. 2004;26:439–46. (PMID: 10.1016/S0149-2918(04)90040-9)
Kassam R, Meneilly GS. Role of the pharmacist on a multidisciplinary diabetes team. Can J Diabetes. 2007;31:215–22. (PMID: 10.1016/S1499-2671(07)13008-2)
Kolawole B, Adebayo R, Aloba O. An assessment of aspirin use in a Nigerian diabetes outpatient clinic. Niger J Med. 2004;13:405–6.
فهرسة مساهمة: Keywords: Contraindications; Diabetes mellitus; Inappropriate prescribing; Omissions; Scoping review
تواريخ الأحداث: Date Created: 20220701 Date Completed: 20220823 Latest Revision: 20230602
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC9393152
DOI: 10.1007/s11096-022-01414-7
PMID: 35776376
قاعدة البيانات: MEDLINE
الوصف
تدمد:2210-7711
DOI:10.1007/s11096-022-01414-7